110 related articles for article (PubMed ID: 38279475)
1. Expression, prognostic value and potential immunotherapeutic target of COL1A1 in colon cancer.
Zeng X; Chen G; Guo D; Chen Y; Hu X
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(15):120-125. PubMed ID: 38279475
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatics analysis identifies COL1A1, THBS2 and SPP1 as potential predictors of patient prognosis and immunotherapy response in gastric cancer.
Wang Y; Zheng K; Chen X; Chen R; Zou Y
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33345281
[TBL] [Abstract][Full Text] [Related]
3. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
[TBL] [Abstract][Full Text] [Related]
4. COL1A1 Is a Potential Prognostic Biomarker and Correlated with Immune Infiltration in Mesothelioma.
Zhang C; Liu S; Wang X; Liu H; Zhou X; Liu H
Biomed Res Int; 2021; 2021():5320941. PubMed ID: 33490271
[TBL] [Abstract][Full Text] [Related]
5. Identification of immune infiltration-related LncRNA FAM83C-AS1 for predicting prognosis and immunotherapy response in colon cancer.
Li G; Feng H; Chen Q; Xue C; Li M; Liu X; Ma S
Transpl Immunol; 2021 Dec; 69():101481. PubMed ID: 34624486
[TBL] [Abstract][Full Text] [Related]
6. Construction and validation of an immune-related genes prognostic index (IRGPI) model in colon cancer.
Jin Y; Deng J; Luo B; Zhong Y; Yu S
Front Endocrinol (Lausanne); 2022; 13():963382. PubMed ID: 36440228
[TBL] [Abstract][Full Text] [Related]
7. A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor.
Mo Z; Li P; Cao Z; Zhang S
Front Immunol; 2021; 12():564948. PubMed ID: 34290693
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy.
Bao X; Zhang H; Wu W; Cheng S; Dai X; Zhu X; Fu Q; Tong Z; Liu L; Zheng Y; Zhao P; Fang W; Liu F
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028695
[TBL] [Abstract][Full Text] [Related]
9. Contribution of endothelial cell-derived transcriptomes to the colon cancer based on bioinformatics analysis.
Wang J; Uddin MN; Akter R; Wu Y
Math Biosci Eng; 2021 Aug; 18(6):7280-7300. PubMed ID: 34814249
[TBL] [Abstract][Full Text] [Related]
10. Exploring immune-related signatures for predicting immunotherapeutic responsiveness, prognosis, and diagnosis of patients with colon cancer.
Cao L; Ba Y; Yang J; Zhang H
Aging (Albany NY); 2022 Jun; 14(12):5131-5152. PubMed ID: 35748788
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the transcriptomic features of microsatellite instability subtype colon cancer.
Wang H; Wang X; Xu L; Zhang J; Cao H
BMC Cancer; 2019 Jun; 19(1):605. PubMed ID: 31221124
[TBL] [Abstract][Full Text] [Related]
12. The Cancer-Associated Fibroblasts-Related Gene COMP Is a Novel Predictor for Prognosis and Immunotherapy Efficacy and Is Correlated with M2 Macrophage Infiltration in Colon Cancer.
Ma H; Qiu Q; Tan D; Chen Q; Liu Y; Chen B; Wang M
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671447
[TBL] [Abstract][Full Text] [Related]
13. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
14. Classification of colon adenocarcinoma based on immunological characterizations: Implications for prognosis and immunotherapy.
Xu M; Chang J; Wang W; Wang X; Wang X; Weng W; Tan C; Zhang M; Ni S; Wang L; Huang Z; Deng Z; Li W; Huang D; Sheng W
Front Immunol; 2022; 13():934083. PubMed ID: 35967414
[TBL] [Abstract][Full Text] [Related]
15. Deoxyribonuclease 1-like 3 may be a potential prognostic biomarker associated with immune infiltration in colon cancer.
Liu J; Yi J; Zhang Z; Cao D; Li L; Yao Y
Aging (Albany NY); 2021 Jun; 13(12):16513-16526. PubMed ID: 34157681
[TBL] [Abstract][Full Text] [Related]
16. Immune cell infiltration-associated signature in colon cancer and its prognostic implications.
Deng D; Luo X; Zhang S; Xu Z
Aging (Albany NY); 2021 Aug; 13(15):19696-19709. PubMed ID: 34349038
[TBL] [Abstract][Full Text] [Related]
17. Autophagy-related gene expression classification defines three molecular subtypes with distinct clinical and microenvironment cell infiltration characteristics in colon cancer.
Zhu S; Wu Q; Zhang B; Wei H; Li B; Shi W; Fang M; Zhu S; Wang L; Lang Zhou Y; Dong Y
Int Immunopharmacol; 2020 Oct; 87():106757. PubMed ID: 32769067
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA‑642a‑5p inhibits colon cancer cell migration and invasion by targeting collagen type I α1.
Wang X; Song Z; Hu B; Chen Z; Chen F; Cao C
Oncol Rep; 2021 Mar; 45(3):933-944. PubMed ID: 33650641
[TBL] [Abstract][Full Text] [Related]
19. Prognostic costimulatory molecule-related signature risk model correlates with immunotherapy response in colon cancer.
Huang W; Su D; Liao X; Yang T; Lu Y; Zhang Z
Sci Rep; 2023 Jan; 13(1):789. PubMed ID: 36646765
[TBL] [Abstract][Full Text] [Related]
20. Bioinformatics analysis of prognostic value and immunological role of MeCP2 in pan-cancer.
Wang Y; Zhang Y; Wang F; Li T; Song X; Shi H; Du J; Zhang H; Jing H; Han J; Tong D; Zhang J
Sci Rep; 2022 Nov; 12(1):18518. PubMed ID: 36323715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
